Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

Abstract Purpose: PI3K–Akt–mTOR and androgen receptor (AR) signaling are commonly
aberrantly activated in metastatic castration-resistant prostate cancer (mCRPC), with PTEN …

Prostate cancer rates vary substantially by race, ethnicity, and geography. These disparities
can be explained by variation in access to screening and treatment, variation in exposure to …

Abstract Background TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …

Prostate cancer (PCa) incidence and mortality have rapidly increased in China. Notably,
unique epidemiological characteristics of PCa are found in the Chinese PCa population …

Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

Prostate cancer has the widest racial disparities of any cancer, and these disparities appear
at every stage of the cancer continuum. This review focuses on the disparities in prostate …

Aneuploidy, defined as chromosome gains and losses, is a hallmark of cancer. However,
compared with other tumor types, extensive aneuploidy is relatively rare in prostate cancer …

Purpose: Inactivation of mismatch repair (MMR) genes may predict sensitivity to
immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with …